High prices restrict access to drugs in low-income countries

The availability of essential medicines for public healthcare in low-income countries is very limited and patients have to buy drugs in the private sector at far higher prices, despite such countries'pharma spending accounting for 20–60% of healthcare budgets.

The availability of essential medicines for public healthcare in low-income countries is very limited and patients have to buy drugs in the private sector at far higher prices, despite such countries'pharma spending accounting for 20–60% of healthcare budgets.

This percentage compares with 18% of healthcare budgets being spent on pharmaceuticals in countries of the Organisation for Economic Co-operation...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip